Seminars in Oncology
Volume 34, Issue 6 , Pages 452-459, December 2007

Genetics: What Advice for Patients Who Present With a Family History of Melanoma?

  • Julia A. Newton Bishop

      Affiliations

    • Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, St James’s Hospital, Leeds, United Kingdom.
    • Corresponding Author InformationAddress correspondence to Julie A. Newton Bishop, MD, FRCP, Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, St James’s Hospital, Leeds, UK LS9 7TF.
  • ,
  • Nelleke A. Gruis

      Affiliations

    • Skin Research Laboratory, Leiden University Medical Center, Leiden, The Netherlands.

A significantly increased susceptibility to melanoma may manifest as a family history of melanoma (plus or minus pancreatic cancer), the development of multiple primary tumors, or melanoma in the context of numerous and clinically atypical moles (the atypical mole syndrome). In families, increased susceptibility may occur as a result of the inheritance of mutations at the CDKN2A locus or in the CDK4 gene. We describe what is known about these genes and discuss the implications for genetic counseling and gene testing. Lower levels of risk are associated with genetically determined pigmentary variation within populations. This variation is attributable to inheritance of variants in the MC1R gene and putatively other genes such as OCA2, which is discussed. Melanoma is causally related to sun exposure in the majority of patients, although the patterns of sun exposure, which are most important, remain controversial. The role of risk estimation for individuals in giving advice about sun exposure is considered.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Cancer Research UK, the NIH (RO1-CA-083115-06), and Framework 6 (J.A.N.B.). Professor Newton Bishop and Dr Gruis are Coordinator and Vice Coordinator, respectively, of GenoMEL, the melanoma genetics consortium (www.genomel.org).

PII: S0093-7754(07)00182-0

doi:10.1053/j.seminoncol.2007.09.006

Seminars in Oncology
Volume 34, Issue 6 , Pages 452-459, December 2007